Isoquinolone BTK Inhibitors Selective Kinase Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors lack selectivity, necessitating the development of novel compounds that can effectively inhibit Bruton's tyrosine kinase (BTK) for treating autoimmune and allergic disorders without affecting other kinases.
Innovation Solution
A novel class of isoquinolone compounds is developed, specifically designed to inhibit BTK, with structures defined by specific chemical formulas and their pharmaceutically acceptable salts or hydrates, which are used to treat autoimmune and allergic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BTK inhibitors are used, then BTK inhibition is achieved, but selectivity is insufficient and other kinases are affected
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the isoquinolone core structure. Different substituents (R1-R6) are placed at specific locations to optimize binding to the BTK active site while avoiding off-target kinase interactions, thereby achieving high selectivity for BTK over other kinases
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and molecular properties of the isoquinolone derivatives. This includes modifying electronic, steric, and hydrophobic parameters through different substituent combinations to achieve optimal BTK selectivity and potency
2Object-affected harmful factors
If novel isoquinolone compounds are developed for high selectivity, then BTK selectivity is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a core isoquinolone structure and separate substituent modules (R1-R6). This modular approach allows systematic optimization of selectivity through combinatorial chemistry while maintaining a manageable core structure, balancing complexity with synthetic feasibility
Solution Approach 2:
The patent employs universality by designing a versatile isoquinolone core scaffold that can accommodate multiple different substituent combinations. This universal platform enables generation of numerous analogs with varying selectivity profiles, allowing efficient exploration of structure-activity relationships without requiring entirely new molecular frameworks
Data Source
AI summary
The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.